IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erickson, K. A.
Right arrow Articles by Schroeder, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erickson, K. A.
Right arrow Articles by Schroeder, A.
(Investigative Ophthalmology and Visual Science. 2000;41:1743-1748.)
© 2000 by The Association for Research in Vision and Ophthalmology, Inc.

Direct Effects of Muscarinic Agents on the Outflow Pathways in Human Eyes

Kristine A. Erickson1,2,3 and Alison Schroeder1

From the Departments of 1 Ophthalmology and 2 Pharmacology, Boston University School of Medicine; and 3 The New England College of Optometry, Boston, Massachusetts.

PURPOSE. Recent studies demonstrating the presence of muscarinic receptors and contractile-like cells in the trabecular meshwork tissue and/or cell cultures from human eyes suggest the possibility that there may be a direct effect of muscarinic agonists on outflow facility. The present studies were conducted to determine whether muscarinic agonists could change outflow facility in perfused human ocular anterior segments, which lack an intact ciliary muscle.

METHODS. Human eyes were dissected and perfused according to previously described methods. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 10-9 to 10-3 M of pilocarpine, aceclidine, or carbachol were added to the perfusion medium. In other studies, 10-6 M atropine was perfused alone followed by 10-7 M carbachol with 10-6 M atropine, whereas fellow control eyes received carbachol alone. Outflow facility was measured for 60 minutes after each drug addition. The outflow facility measurement in each eye after drug administration was compared with the baseline measurement.

RESULTS. Outflow facility increased from baseline facility in eyes treated with pilocarpine, aceclidine, or carbachol at lower concentrations (10-9 to 10-6 M) but remained unchanged at higher concentrations (10-4 to 10-2 M). The effects of carbachol at 10-7 M were completely blocked by atropine.

CONCLUSIONS. Muscarinic agonists increase outflow facility in human eyes by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect is biphasic, occurring at concentrations of 10-6 M and lower with no effect at higher concentrations.




This article has been cited by other articles:


Home page
Br. J. Ophthalmol.Home page
Z Gatzioufas, P Charalambous, B Seitz, S Evers, C Jonescu-Cuypers, M Krause, and S Thanos
Cholinergic inhibition by botulinum toxin in a rat model of congenital glaucoma raises intraocular pressure
Br. J. Ophthalmol., June 1, 2008; 92(6): 826 - 831.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
Z. Wan, D. F. Woodward, C. L. Cornell, H. G. Fliri, J. L. Martos, S. N. Pettit, J. W. Wang, A. B. Kharlamb, L. A. Wheeler, M. E. Garst, et al.
Bimatoprost, Prostamide Activity, and Conventional Drainage
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4107 - 4115.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Association for Research in Vision and Ophthalmology